According to the latest market research study published by P&S Intelligence, the global pharmacovigilance market is poised for significant growth, with projections indicating a rise from USD 8,340.1 million in 2024 to USD 18,026.7 million by 2030, reflecting a CAGR of 13.9%. This expansion is primarily driven by the increasing incidence of adverse drug reactions (ADRs) and a heightened focus on drug safety and efficacy. Additionally, the integration of artificial intelligence (AI) and machine learning (ML) into pharmacovigilance systems is enhancing the detection, analysis, and prediction of ADRs, further propelling market growth.
Key Insights
Segmentation Analysis:
- Product Life Cycle: The pharmacovigilance market encompasses various stages, including pre-clinical, Phase I, Phase II, Phase III, and Phase IV.
- Service Providers: Services are offered both in-house and by third-party providers, catering to the diverse needs of pharmaceutical and biotechnology companies.
- Services Offered: Key services include spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and electronic health record (EHR) mining.
- Process Flow: The process flow in pharmacovigilance involves case data management, signal detection, and risk management systems.
- Therapeutic Areas: The market serves multiple therapeutic areas, notably oncology, neurology, cardiology, and pulmonology.
Regional and Geographical Trends:
- North America: Currently holds the largest market share, attributed to advanced healthcare infrastructure and stringent drug safety regulations.
- Asia-Pacific: Anticipated to experience the fastest growth, driven by increasing healthcare investments, rising awareness of drug safety, and expanding pharmaceutical industries in countries like China and India.
Technological Advancements Shaping the Market:
- Artificial Intelligence and Machine Learning: The adoption of AI and ML technologies is revolutionizing pharmacovigilance by improving the efficiency and accuracy of ADR detection and analysis.
- Personalized Medicine: The shift towards personalized medicine necessitates advanced pharmacovigilance practices to monitor individualized therapies, ensuring safety and efficacy tailored to genetic profiles.
Competitive Dynamics, Major Players, and Emerging Opportunities:
- Market Fragmentation: The pharmacovigilance market is characterized by fragmentation, with a mix of large multinational pharmaceutical companies, specialized service providers, and regional firms.
- Key Players: Prominent companies include Accenture plc, Bristol-Myers Squibb Company, Cognizant Technology Solutions Corporation, GlaxoSmithKline plc, ICON plc, Novartis AG, F. Hoffmann-La Roche Ltd., Pfizer Inc., and Wipro Limited.
- Emerging Opportunities: The increasing complexity of drug therapies and the global expansion of pharmaceutical markets present opportunities for specialized pharmacovigilance services, particularly in emerging economies.
About P&S Intelligence
P&S Intelligence offers custom and syndicated market research and consulting services to clients across the globe. Our team of young and dynamic researchers, guided by mentors with years of experience, create data-rich reports tailored to the needs of MNCs as well as startups and SMEs. We remain in a perennial quest to offer exhaustive insights into every aspect of the market, allowing businesses of all sizes to seize even the smallest of opportunities and tackle even the biggest of challenges.
Comments